Orient Bio Chairman Jang Jae-jin Launches 'Safe Driving' Campaign with Seongnam Jungwon Police to Spread Industrial Park Safety Culture
Predicted impact: Low
Chairman's local police safety campaign; no financial relevance.
Orientbio오리엔트바이오
002630 · KOSPI · ₩002630 · 오리엔트바이오
₩1,229▼ ₩59 (4.58%)End-of-day · Oct 29, 2026 · End-of-day prices.
Price · 1Y −48.70%
- Market cap
- ₩36B
- Enterprise value
- −₩1.5B
- P/E
- —
- P/B
- 0.5×
- Dividend yield
- 0.0%
- ROE
- −8.7%
- Net margin
- −22.3%
Trailing 12 months from filed financial statements, as of Q1 2026. Dividend yield: the 2025 dividend per share from the annual report ÷ today's price.
52-week range−64.5% from the high
₩1,209Today: ₩1,209 – ₩1,300₩3,460
Returns
- 1W−10.9%
- 1M−27.7%
- 3M−31.8%
- 6M−46.0%
- YTD−51.8%
- 1Y−48.7%
- Volume today
- 45,941
- 0.8× the 20-day average
- Traded today
- ₩57M
- Listed shares
- 29,645,751
- EPS (12 months)
- −₩213
- Earnings yield −17.3%
AI researchResearch being writtenOur AI is writing a report on this company from filed data, prices and news. Check back soon.
Upcoming dates
Full calendar →🎁 Gift this stock
Send a friend ₩100,000 of paper money in this stock. They get it when they join.
Signals
Quiet- BuzzQuietBuzz 39 of 100 (50 is a normal day for this stock).
- MomentumWeak-31.5% over the last month; the price is below its 20-day average.
- News impactLow1 news items and filings in two weeks; 0 rated high impact, 0 medium.
Signals describe activity, not recommendations. Not financial advice.
Orientbio stock overview
Orientbio (오리엔트바이오, KRX: 002630) is listed on KOSPI, in the Biotech & Pharma sector. The company supplies laboratory animals and related biological materials for drug development, including Charles River-licensed rodents, beagle dogs, primates, SPF eggs and vaccine-production mice. Its shares closed at ₩1,229 on Oct 29, 2026, down 4.58% on the day, giving it a market value of ₩36B.
Key facts
- Market cap
- ₩36B
- Sector
- Biotech & Pharma
- Latest price change
- −4.58%
- As of
- Oct 29, 2026
- Main business
- The company supplies laboratory animals and related biological materials for drug development, including Charles River-licensed rodents, beagle dogs, primates, SPF eggs and vaccine-production mice.
Quick answers about Orientbio
- What does Orientbio do?
- The company supplies laboratory animals and related biological materials for drug development, including Charles River-licensed rodents, beagle dogs, primates, SPF eggs and vaccine-production mice. It also develops and manufactures medical and laboratory equipment and operates a corporate research center. Its customers include universities, hospitals and pharmaceutical companies, and its main facilities are in Gyeonggi Province, Korea.
- What is the market cap of Orientbio?
- The market capitalisation of Orientbio was ₩36B at the close on Oct 29, 2026.
- Who are the largest shareholders of Orientbio?
- According to the latest official filings, the largest reported holders are Orient (28.55%, as of Sep 17, 2026); Choi Sook-jong (2.77%, as of Sep 17, 2026); Jang Jae-jin (0.76%, as of Sep 17, 2026).
- When is the next earnings report from Orientbio?
- Korean companies rarely announce results dates in advance. Based on when Orientbio filed the same report in past years, its next 2q results is expected around Nov 14, 2026.
- Does the National Pension Service own Orientbio?
- Yes. The National Pension Service held 0.06% of Orientbio shares as of Dec 31, 2024.
Company profile
The company supplies laboratory animals and related biological materials for drug development, including Charles River-licensed rodents, beagle dogs, primates, SPF eggs and vaccine-production mice. It also develops and manufactures medical and laboratory equipment and operates a corporate research center. Its customers include universities, hospitals and pharmaceutical companies, and its main facilities are in Gyeonggi Province, Korea.
Written by AI from the company's latest annual report.
- Korean name
- 오리엔트바이오
- Sector
- Biotech & Pharma
- Themes
- Biotech (new drugs)
- CEO
- 장재진
- Founded
- Apr 1959
- Listed
- Dec 1976
- Listed shares
- 29,645,751
- Fiscal year ends
- Month 03
- Website
- www.orientbio.co.kr/
Similar companies
- Samsung Biologics207940 · ₩63T₩1,366,000−0.44%
- Celltrion068270 · ₩44T₩189,300−0.26%
- Alteogen196170 · ₩15T₩220,000−1.35%
- SK biopharmaceuticals326030 · ₩6.1T₩77,800+3.46%
- Yuhan000100 · ₩5.5T₩74,700−3.36%
- HLB028300 · ₩5.3T₩39,700−2.34%
- Hanmi Pharm128940 · ₩5T₩388,500+5.14%
- SAM Chun Dang Pharm000250 · ₩4.4T₩188,600−0.74%
Recent news
Recent filings
See all- Insider shareholding reportSep 17, 2026
- Insider shareholding reportSep 17, 2026
- Insider shareholding reportSep 17, 2026
- 5%+ holding reportSep 4, 2026
- Insider shareholding reportSep 4, 2026
Titles in Korean until English translations are added.
Also known as: Orientbio / 오리엔트바이오 / 002630 / KRX:002630
Source: KRX statistical information